0001831283-23-000041 Sample Contracts
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • March 28th, 2023 • LianBio • Pharmaceutical preparations • New York
THIS LICENSE AND COLLABORATION AGREEMENT (this “Agreement”), entered into as of February 28, 2023 (the “Effective Date”), is entered into by and between LianBio Development (HK) Limited, a company limited by shares organized and existing under the laws of Hong Kong Special Administrative Region of the People’s Republic of China (“Lian”), and NImmune Biopharma, Inc., a company organized and existing under the laws of the State of Delaware (“Licensor”).
Standard Contracts
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL COMMERCIALIZATION AGREEMENT WITH RESPECT TO SISUNATOVIR BY...Commercialization Agreement • March 28th, 2023 • LianBio • Pharmaceutical preparations • New York
(1)LianBio Development (HK) Limited, a limited liability company organized under the laws of Hong Kong, having an address at RM 1901, 19/F Lee Garden One 33 Hysan Avenue, Causeway Bay HK (“LianBio Development”);
December 12, 2022 Debra Yu Dear Debra:Consulting Agreement • March 28th, 2023 • LianBio • Pharmaceutical preparations
This letter (this “Agreement”) confirms the terms of your engagement to provide consulting services to LianBio, an exempted company organized under the laws of the Cayman Islands (the “Company”).
AMENDMENT NO. 1 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • March 28th, 2023 • LianBio • Pharmaceutical preparations
This Amendment No. 1 to the License, Development and Commercialization Agreement (this “Amendment No. 1”) is entered into on March 16, 2023, by and between Nanobiotix S.A., a French société anonyme having its registered office located at 60 Rue de Wattignies, 75012, Paris, France, registered under number 447 521 600 (RCS Paris) (“Nanobiotix”), and Lian Oncology Limited, a Hong Kong company limited by shares, having its principal place of business located at Rooms 05-15, 13A/F, South Tower, World Finance Centre, Harbour City, 17 Canton Road, Tsim Sha Tsui, Kowloon, Hong Kong (formerly Room 1902, 10/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong) (“Lian”). Nanobiotix and Lian are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • March 28th, 2023 • LianBio • Pharmaceutical preparations
THIS FIRST AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENT (this “Amendment”) is made as of February 28, 2023 (the “Amendment Effective Date”) by and between LianBio Respiratory Limited (“Lian”) and Landos BioPharma, Inc. (“Landos”).
December 9, 2022 Via PDF Email ([***]) Debra YuResignation Agreement • March 28th, 2023 • LianBio • Pharmaceutical preparations
As we discussed, LianBio, LLC, a limited liability company organized under the laws of the State of Delaware (the “Company”), has accepted your resignation and your employment with the Company shall terminate, effective as of January 1, 2023 (the “Resignation Date”). The purpose of this letter (the “Agreement”) is to confirm the terms concerning your resignation. Capitalized terms not defined herein shall have the respective meanings ascribed to them in the Amended and Restated Executive Employment Agreement between you and the Company, dated September 14, 2021 (the “Employment Agreement”).
Employment Contract Execution Date: March 14, 2023Employment Contract • March 28th, 2023 • LianBio • Pharmaceutical preparations
Shanghai LianBio Development Co., Ltd., having its registered address at 3rd Floor, Building 1, No. 400 Fangchun Road, China (Shanghai) Pilot Free Trade Zone, and with Yizhe Wang as its legal representative (the “Company”); and
